Abstracts Archive - Page 1712 of 2607 - ACR Meeting Abstracts

Abstract Number: 1692 • 2016 ACR/ARHP Annual Meeting
Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Jessica Mounessa¹, Darren Lynn¹, Jessica Walsh², Mena Hashim¹, Ryan Duong³, Robert Dellavalle¹ and Liron Caplan¹, ¹Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ³Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO
Background/Purpose: While the psoriasis area and severity index (PASI) is the most commonly used assessment tool for psoriasis severity, it has been criticized for its…
Abstract Number: 1693 • 2016 ACR/ARHP Annual Meeting
Chronic Back Pain in Early Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R. Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Hans L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, Johanna M.W. Hazes¹¹ and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Gasthuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ¹¹Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Axial involvement is less well studied in peripheral spondyloarthritis where chronic back pain is not the predominant symptom, such as in psoriatic arthritis (PsA).…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…
Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…
Abstract Number: 1697 • 2016 ACR/ARHP Annual Meeting
Validity of Diagnostic Codes and Point Prevalence of Psoriatic Arthritis in Israel – a Population-Based Study
Lihi Eder¹, Arnon Dov Cohen^2,3, Ilan Feldhamer³, Sari Greenberg-Dotan³, Erez Batat³ and Devy Zisman^4,5, ¹Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Siaal Research Center for Family Medicine and Primary Care, Ben-Gurion University of the Negev, Beer-Sheba, Israel, ³Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁴The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ⁵Department of Rheumatology, Carmel Medical Center, Haifa, Israel
Background/Purpose: The information on the population-based prevalence of Psoriatic Arthritis (PsA) is limited. Large population-based databases provide an opportunity to study the epidemiology of PsA,…
Abstract Number: 1698 • 2016 ACR/ARHP Annual Meeting
Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Ari Polachek¹, Roa'a Al Johani², Suzanne Li¹, Vinod Chandran¹ and Dafna D Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd to 5th decades of life. However, little is known about PsA activity and prognosis among patients…
Abstract Number: 1699 • 2016 ACR/ARHP Annual Meeting
RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis
Laura C. Coates^1,2, William Tillett^3,4, Theodore Pincus⁵, Arthur Kavanaugh⁶ and Philip S. Helliwell⁷, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁴Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Rheumatology, Rush University Medical Center, Chicago, IL, ⁶Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ⁷NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: RAPID3 (routine assessment of patient index data) is a patient self-report index which is feasible in busy clinical settings to assess severity and change…
Abstract Number: 1700 • 2016 ACR/ARHP Annual Meeting
Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Matthew Got¹, Suzanne Li², Anthony V. Perruccio^3,4, Dafna D Gladman¹ and Vinod Chandran⁵, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: PASDAS is a composite disease activity measure (range 0–10) for psoriatic arthritis (PsA). Recently, PASDAS disease activity cutoffs were proposed and a minimal disease…
Abstract Number: 1701 • 2016 ACR/ARHP Annual Meeting
The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Agnes Szentpetery¹, Natsumi Ikumi¹, Brian Kirby² and Oliver FitzGerald³, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
Background/Purpose: Depression and anxiety are well known comorbidities in psoriasis (PsO) and psoriatic arthritis (PsA) with higher prevalence in PsA. Patients with PsA have…
Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Christopher T. Ritchlin⁴, Doquyen H. Huynh³, Renganayaki Pandurengan², Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Peter Nash¹, Kamal Ohson², Jessica Walsh³, Nikolay Delev⁴, Dianne Nguyen⁴, Lichen Teng⁴, Juan J Gomez-Reino⁵ and Jacob A Aelion⁶, ¹University of Queensland, Brisbane, Australia, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Celgene Corporation, Summit, NJ, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…
Abstract Number: 1704 • 2016 ACR/ARHP Annual Meeting
Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Philip J Mease¹, Iain B McInnes², Kristian Reich³, Mats Andersson⁴, Aiyang Tao⁵, Todd Fox⁴ and Chetan Karyekar⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Glasgow, Glasgow, Great Britain, ³Dermatologikum Hamburg and Georg-August-University Göttingen, Hamburg, Germany, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Pooled safety data from the psoriasis (PsO) and psoriatic arthritis (PsA) clinical trial programs of secukinumab (SEC), through approximately 1 year, have been reported…
Abstract Number: 1705 • 2016 ACR/ARHP Annual Meeting
The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Lauren Harter¹, Daniel Shin², Joshua F. Baker³, Junko Takeshita², Thorvardur Love^4,5, Joel Gelfand⁶ and Alexis Ogdie⁷, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²University of Pennsylvania, Philadelphia, PA, ³Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵Landspitali University Hospital, Reykjavík, Iceland, ⁶University of Pennsylvania Health System , Philadelphia, PA, ⁷Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While rheumatoid arthritis (RA) has been linked to an increased incidence of osteoporosis (OP) and fracture, few studies have examined the risk of fracture…
Abstract Number: 1706 • 2016 ACR/ARHP Annual Meeting
Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R. Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Hans L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, Johanna M.W. Hazes¹¹ and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Gasthuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ¹¹Department of Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a multifaceted disease. Affecting joints, skin, entheses and dactylitis, its impact on health-related quality-of-life (HRQoL) could be substantial. Up to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].